ABG
PRAX icon

Ally Bridge Group’s Praxis Precision Medicines PRAX Stock Holding History

Ally Bridge Group’s Portfolio PRAX Stock Details PRAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-100,000
Closed -$5.3M – 28
2025
Q3 		$5.3M Buy
+100,000
New +$4.85M 3.23% 13

Other funds holding PRAX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Ally Bridge Group's PRAX Position: Q1 2026 in Review

Ally Bridge Group increased its Praxis Precision Medicines (PRAX) stake by 65% in Q1 2026, buying an estimated $4M and bringing the position to 32,810 shares worth $10.6M. The position accounts for 8.54% of the portfolio, ranked #1.

Ally Bridge Group first reported a position in PRAX in Q4 2022 and has held it in 12 quarters since. 289 funds tracked by Wall St. Rank hold PRAX as of Q1 2026.

  • Ally Bridge Group held 32,810 shares of Praxis Precision Medicines worth $10.6M as of Q1 2026.
  • Ally Bridge Group bought 12,928 Praxis Precision Medicines shares in Q1 2026, an estimated $4M.
  • Praxis Precision Medicines made up 8.54% of Ally Bridge Group's portfolio in Q1 2026, its #1 holding.
  • Ally Bridge Group first reported a position in Praxis Precision Medicines in Q4 2022 and has held it in 12 quarters since.
  • 289 funds tracked by Wall St. Rank held Praxis Precision Medicines as of Q1 2026.

Based on Ally Bridge Group's 13F filing for Q1 2026, filed 18 May 2026.